Results 161 to 170 of about 318,932 (267)

Clock Genes Regulate Ca2+ Signaling and Mitochondrial Bioenergetics to Inhibit Sjögren Disease

Arthritis &Rheumatology, EarlyView.
Objective Although Ca2+ signaling and metabolism have been identified as key determinants for the development of Sjögren disease (SjD), the intricate connection between them and salivary gland physiology remains poorly understood. Methods Fluorescence‐based Ca2+ imaging, RNA sequencing, and mitochondrial activity were used to investigate the effects of
Viktor R. Drel, Manigandan Venkatesan, Rahul S. Jasrotia, Yuyang Sun, Viviane Nascimento da Conceicao, Neelanjan Vishnu, Shankara N. Varadarajan, Venugopal R. Bovilla, Rajender K. Motiani, Shobhan Gaddameedhi, Bibhuti B. Mishra, Muniswamy Madesh, Brij B. Singh   +12 more
wiley   +1 more source

Care Patterns, Outcomes, and Costs in Peripheral T-Cell Lymphoma Patients with First-Line Treatment in Routine Clinical Practice in Europe. [PDF]

J Blood Med
Kristo F, Kelkar SS, Raina R, Schmier JK, Dalal MR, Ashaye AO.   +5 more
europepmc   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting. [PDF]

Exp Hematol Oncol
Feng S, Kong R, Xiao L, Zhou X.
europepmc   +1 more source

Homocitrullinated Peptides Drive Pro‐Inflammatory T Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova, Jaspreet Kaur, Gabrielle Buckley, S. M. Mansour Haeryfar, Lisa Cameron, Ewa Cairns, Lillian Barra   +6 more
wiley   +1 more source

Distinct molecular pathways supporting Sjögren's Disease clusters and disease progression.

Arthritis &Rheumatology, Accepted Article.
Objective Sjögren's disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined SjD patient clusters: (1) B‐cell active with low symptoms (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptoms (LSAHS).
Sacha E Silva‐Saffar, Yann Nguyen, Raphaèle Seror, Jacques‐Eric Gottenberg, Anna Niarakis, Xavier Mariette, Gaetane Nocturne   +6 more
wiley   +1 more source

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy. [PDF]

Blood Adv
Xu R, Wu G, Rice S, Booker M, Weekes J, Bell H, Gao Y, Nirmal AJ, Liu H, Ciantra Z, Luo Q, Fortune A, Whalen K, Guanci T, Wan Y, Louissaint A, Nordberg JJ, Lin JR, Hemann M, Manalis SR, Armand P, Smith E, Jacobson CA, Tolstorukov M, Murakami MA, Sorger PK, Weinstock DM, Song L, Lane AA.   +28 more
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

CAR-T cell therapy in non-Hodgkin lymphoma: a clinical trial landscape review. [PDF]

Front Immunol
Wu J, Liao Y, Wang W, Zhang X.
europepmc   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source